Filing Flows › Bristol Myers Squibb (BMY) › How it makes money
How Bristol Myers Squibb (BMY) makes money
Bristol Myers Squibb (BMY) made $13.1B of revenue in the third quarter 2026 (Q3 2026), +14% from a year earlier. Net product sales brought in $12.6B (97%); Camzyos brought in $420M (3%). Of every dollar of revenue, 19¢ was left as operating profit, 17¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Net product sales | $12.6B | 96.8% | — | +13% |
| ↳ Legacy Portfolio | $5.4B | 41.5% | — | +0.9% |
| ↳ Eliquis | $4.7B | 35.9% | — | +25% |
| ↳ Yervoy | $793M | 6.1% | — | +7% |
| ↳ Reblozyl | $750M | 5.7% | — | +22% |
| ↳ Breyanzi | $526M | 4.0% | — | +47% |
| ↳ Alliance and other revenues | $463M | 3.5% | — | +24% |
| Camzyos | $420M | 3.2% | — | +42% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $13.1B | 100.0% |
| Operating profit | $2.5B | 19.4% |
| Income tax | $374M | 2.9% |
| Net earnings | $2.2B | 16.6% |
| Operating cash flow | $4.2B | 32.0% |
| Free cash flow | $3.8B | 29.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $13.1B | +7% |
| Q2 2026 | $13.0B | +6% |
| Q1 2026 | $11.5B | +3% |
| Q4 2025 | $12.5B | +1% |
| Q3 2025 | $12.2B | +3% |
| Q2 2025 | $12.3B | +0.6% |
| Q1 2025 | $11.2B | -6% |
From Bristol Myers Squibb's 10-Q filed Oct 29, 2026 (on EDGAR).
Questions
How does Bristol Myers Squibb make money?
Bristol Myers Squibb (BMY) made $13.1B of revenue in the third quarter 2026 (Q3 2026), +14% from a year earlier. Net product sales brought in $12.6B (97%); Camzyos brought in $420M (3%). Of every dollar of revenue, 19¢ was left as operating profit, 17¢ was left as net earnings.
What is Bristol Myers Squibb's biggest business?
Net product sales: $12.6B in the third quarter 2026, 97% of revenue, +13% from a year earlier.
What is Bristol Myers Squibb's profit margin?
Net earnings were $2.2B, 16.6% of revenue, in the third quarter 2026; the operating margin was 19.4%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.